Repository of Research and Investigative Information

Repository of Research and Investigative Information

Kurdistan University of Medical Sciences

Celecoxib adjunctive therapy for acute bipolar mania: A randomized, double-blind, placebo-controlled trial

(2015) Celecoxib adjunctive therapy for acute bipolar mania: A randomized, double-blind, placebo-controlled trial. Bipolar Disorders.

Full text not available from this repository.

Official URL:


Objectives: Recent research has focused on the inflammatory cascade as a key culprit in the etiology of bipolar disorder. We hypothesized that celecoxib, via its anti-inflammatory properties, may have a therapeutic role in mood disorder. Methods: Forty-six inpatients with the diagnosis of acute bipolar mania without psychotic features participated in a parallel, randomized, double-blind, placebo-controlled trial, and underwent six weeks of treatment with either celecoxib (400 mg daily) or placebo as an adjunctive treatment to sodium valproate. Patients were evaluated using the Young Mania Rating Scale (YMRS) and Hamilton Depression Rating Scale (HDRS). The primary outcome measure with respect to efficacy was the mean decrease in YMRS score from baseline to the study endpoint, which was compared between the two groups. Results: A significant difference was observed in the change in YMRS scores on Day 42 compared to baseline in the two groups (p < 0.001). The changes at the endpoint compared to baseline were -29.78 ± 21.78 (mean ± standard deviation) and -21.78 ± 7.16 for the celecoxib and placebo groups, respectively. A significantly higher remission rate was observed in the celecoxib group (87.0) than the placebo group (43.5) at Week 6 (p = 0.005). General linear model repeated measures demonstrated a significant effect for the time × treatment interaction on the YMRS scores F(2.27,99.98) = 6.67, p = 0.001. Conclusions: Celecoxib is an effective adjuvant therapy in the treatment of manic episodes (without psychotic features) of bipolar mood disorder. The mood-stabilizing role of the drug might be mediated via its action on the inflammatory cascade. © 2015 John Wiley & Sons A/S.

Item Type: Article
Keywords: carbamazepine; celecoxib; interleukin 2; interleukin 4; interleukin 6; lithium; lorazepam; mood stabilizer; olanzapine; placebo; risperidone; valproic acid; celecoxib; cyclooxygenase 2 inhibitor; valproic acid, abdominal pain; add on therapy; adult; antiinflammatory activity; appetite disorder; Article; bipolar disorder; bipolar mania; clinical article; constipation; controlled study; diarrhea; dizziness; double blind procedure; drowsiness; drug efficacy; fatigue; female; Hamilton Depression Rating Scale; human; male; mood disorder; outcome assessment; parallel design; physical examination; prevalence; priority journal; randomized controlled trial; remission; restlessness; scoring system; Young Mania Rating Scale; bipolar disorder; drug combination; inflammation; pathophysiology; psychological rating scale; treatment outcome, Adult; Bipolar Disorder; Celecoxib; Cyclooxygenase 2 Inhibitors; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Inflammation; Male; Psychiatric Status Rating Scales; Treatment Outcome; Valproic Acid
Page Range: pp. 606-614
Journal or Publication Title: Bipolar Disorders
Volume: 17
Number: 6
Publisher: Blackwell Publishing Inc.
Identification Number: 10.1111/bdi.12324
ISSN: 13985647
Depositing User: مهندس جمال محمودپور

Actions (login required)

View Item View Item